Clinical trial
A Phase 1A, First in Human, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of PMG1015 in Healthy Volunteers
NCT05022771 is registered in ClinicalTrials.gov with Pulmongene Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1A, First in Human, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of PMG1015 in Healthy Volunteers
- Lead sponsor
- Pulmongene Ltd.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- October 14, 2021
- Completion date
- August 18, 2022
- Enrollment
- 54 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.